Merus Competitors

Merus (NASDAQ:MRUS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Insider and Institutional Ownership

62.6% of Merus shares are held by institutional investors. Comparatively, 79.1% of Intra-Cellular Therapies shares are held by institutional investors. 7.4% of Merus shares are held by insiders. Comparatively, 18.2% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Merus and Intra-Cellular Therapies' top-line revenue, earnings per share and valuation.

Merus has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Merus and Intra-Cellular Therapies, as provided by MarketBeat.

Merus currently has a consensus price target of $23.50, suggesting a potential downside of 0.97%. Intra-Cellular Therapies has a consensus price target of $47.4286, suggesting a potential upside of 31.89%. Given Intra-Cellular Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Intra-Cellular Therapies is more favorable than Merus.

Profitability

This table compares Merus and Intra-Cellular Therapies' net margins, return on equity and return on assets.

Risk & Volatility

Merus has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.

Summary

Intra-Cellular Therapies beats Merus on 8 of the 14 factors compared between the two stocks.

Merus (NASDAQ:MRUS) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Earnings & Valuation

This table compares Merus and Xencor's revenue, earnings per share (EPS) and valuation.

Xencor has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Merus has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Profitability

This table compares Merus and Xencor's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Merus and Xencor, as reported by MarketBeat.com.

Merus presently has a consensus price target of $23.50, suggesting a potential downside of 0.97%. Xencor has a consensus price target of $47.1111, suggesting a potential downside of 2.14%. Given Merus' stronger consensus rating and higher probable upside, research analysts plainly believe Merus is more favorable than Xencor.

Insider & Institutional Ownership

62.6% of Merus shares are owned by institutional investors. 7.4% of Merus shares are owned by company insiders. Comparatively, 3.7% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Merus (NASDAQ:MRUS) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings.

Institutional and Insider Ownership

62.6% of Merus shares are held by institutional investors. Comparatively, 11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. 7.4% of Merus shares are held by insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Merus and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Merus and Taro Pharmaceutical Industries' top-line revenue, earnings per share and valuation.

Taro Pharmaceutical Industries has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Merus and Taro Pharmaceutical Industries, as reported by MarketBeat.com.

Merus presently has a consensus price target of $23.50, indicating a potential downside of 0.97%. Taro Pharmaceutical Industries has a consensus price target of $81.00, indicating a potential upside of 12.83%. Given Taro Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts plainly believe Taro Pharmaceutical Industries is more favorable than Merus.

Risk & Volatility

Merus has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.

Summary

Taro Pharmaceutical Industries beats Merus on 10 of the 14 factors compared between the two stocks.

Prelude Therapeutics (NASDAQ:PRLD) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Prelude Therapeutics and Merus' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for Prelude Therapeutics and Merus, as provided by MarketBeat.

Prelude Therapeutics presently has a consensus price target of $41.3333, indicating a potential downside of 37.43%. Merus has a consensus price target of $23.50, indicating a potential downside of 0.97%. Given Merus' stronger consensus rating and higher possible upside, analysts clearly believe Merus is more favorable than Prelude Therapeutics.

Insider and Institutional Ownership

76.2% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Merus shares are held by institutional investors. 7.4% of Merus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Prelude Therapeutics and Merus' top-line revenue, earnings per share and valuation.

Prelude Therapeutics has higher earnings, but lower revenue than Merus.

Summary

Merus beats Prelude Therapeutics on 5 of the 9 factors compared between the two stocks.

Merus (NASDAQ:MRUS) and IGM Biosciences (NASDAQ:IGMS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.

Institutional and Insider Ownership

62.6% of Merus shares are owned by institutional investors. Comparatively, 47.6% of IGM Biosciences shares are owned by institutional investors. 7.4% of Merus shares are owned by insiders. Comparatively, 79.3% of IGM Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Merus and IGM Biosciences' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Merus and IGM Biosciences' gross revenue, earnings per share (EPS) and valuation.

IGM Biosciences has lower revenue, but higher earnings than Merus. IGM Biosciences is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Merus has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of -1.12, suggesting that its stock price is 212% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Merus and IGM Biosciences, as provided by MarketBeat.

Merus presently has a consensus price target of $23.50, indicating a potential downside of 0.97%. IGM Biosciences has a consensus price target of $96.00, indicating a potential upside of 6.63%. Given IGM Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe IGM Biosciences is more favorable than Merus.

Summary

IGM Biosciences beats Merus on 8 of the 13 factors compared between the two stocks.

Global Blood Therapeutics (NASDAQ:GBT) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Risk & Volatility

Global Blood Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, Merus has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Global Blood Therapeutics and Merus, as reported by MarketBeat.

Global Blood Therapeutics presently has a consensus price target of $93.8235, suggesting a potential upside of 115.04%. Merus has a consensus price target of $23.50, suggesting a potential downside of 0.97%. Given Global Blood Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Global Blood Therapeutics is more favorable than Merus.

Valuation and Earnings

This table compares Global Blood Therapeutics and Merus' gross revenue, earnings per share and valuation.

Merus has higher revenue and earnings than Global Blood Therapeutics. Merus is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Global Blood Therapeutics and Merus' net margins, return on equity and return on assets.

Insider & Institutional Ownership

62.6% of Merus shares are held by institutional investors. 4.3% of Global Blood Therapeutics shares are held by insiders. Comparatively, 7.4% of Merus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Merus beats Global Blood Therapeutics on 8 of the 14 factors compared between the two stocks.